Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Antengene Developed World’s First XPOVIO® for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Antengene has approved New Drug Application (NDA) for XPOVIO® (selinexor) in combination with dexamethasone for the treatment of relapsed and/or refractory multiple myeloma (R/R MM) patients who have received multiple prior therapies.

XPOVIO® stands as the world's pioneering orally-available, selective inhibitor of the nuclear export protein XPO1, with its approval marking a groundbreaking milestone. 

Its novel mechanism of action introduces a fresh approach to treatment, complemented by the potential for synergistic effects within combination regimens. Notably, XPOVIO® exhibits rapid onset of action, contributing to its ability to yield prompt and enduring responses in patients.

XPOVIO® (selinexor) in combination with dexamethasone is designed for the treatment of adult patients with relapsed and/or refractory multiple myeloma (R/R MM) who have undergone at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors (PIs), two immunomodulatory agents (IMiDs), and an anti-CD38 monoclonal antibody, and who have shown disease progression on the last therapy.

Through its inhibition of the nuclear export protein XPO1, XPOVIO® prompts the accumulation and activation of tumour suppressor proteins and growth-regulating molecules within the cell nucleus. Furthermore, it leads to a reduction in the levels of various oncogenic proteins.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024